Use m- iodobenzylguanidine treatment malignant pheochromocytoma efficacy safety m- iodobenzylguanidine MIBG patients malignant pheochromocytomas nonrandomized single arm trial patients MIBG SA megabequerel/mg months patients bone soft tissue metastases soft metastases bone metastases follow-up period months number doses mCi gigabequerel GBq mCi /administration cumulative activity GBq mCi absorbed cumulative dose tumors Gy beneficial effect treatment patients complete remission disease Seven patients study treatment Seven hormonal responses complete partial duration months patients months patients partial tumoral responses soft tissues duration months patients hormonal response objective improvement clinical status blood pressure clear-cut relationship cumulative dose responses main side-effect patient widespread bone metastases doses GBq pancytopenia treatment study MIBG treatment effective patients advanced malignant pheochromocytoma 